Market Research Report
Global Depression Treatment Therapy Market Research and Forecast, 2018-2023
|Published by||Orion Market Research Pvt Ltd||Product code||425901|
Delivery time: 2-3 business days
|Global Depression Treatment Therapy Market Research and Forecast, 2018-2023|
|Published: March 6, 2018||Content info:||
Global depression treatment market is facing stiff decline. The market is expected to grow at low CAGR of 2.1% for the forecasted period of 2018-2023. One of the major factors for such low growth is a rapid decline in the revenue of branded drug manufacturers and growing strength of generic drug manufacturers. The patent cliff has caused a decline in revenues ranging from few million dollars to billions. The patent expiration and generic drug manufacturers gaining license to manufacturers have forced many branded drug manufacturers to either stop their R&D or to reduce budgets. There are very limited number of new drugs in the pipeline. Decline in revenues is majorly due to fall in the price of once expensive drugs by over 50-90%. Volume shipment is still high and increasing especially in emerging markets.
However, markets for therapies using medical devices such as Vagus nerve stimulation, deep brain stimulation, and smartphones is rising. The devices market is expected to grow at a CAGR of 9.2%. The introduction of virtual reality in the treatment of disorders such as post-traumatic stress disorders is also driving the market.
North America and Europe currently are the leading markets. They make up for 70% of the total depression treatment market. The markets are driven by high awareness regarding depression and availability of drugs and therapies. However, the patent cliff has caused a decline in the growth rates of the market. Asia Pacific will have the highest growth rate. Recently the discussion over effects of depression on the economies has been going on. Countries such as India, China and Japan are spending on the research of new treatment methods for treating depression. It is expected that new Asian companies could develop new branded drugs in the near future.
The key players included in the report are: Pfizer, Teva Pharmaceuticals, Johnson and Johnson, Merck & Co., Eli lily and company, Novartis, Sanofi-Aventis, AstraZeneca, and others.
Global depression treatment therapy market by depression type
Global depression treatment therapy market by drugs type
Global depression treatment therapy market by depression treatment device
The market study of depression market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
Supplier Websites such as Alibaba, amazon for pricing analysis.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
The Report covers:
Comprehensive research methodology of Global depression treatment therapy Market.
This report also includes detailed and extensive market overview with Analyst insights & key market trends.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global depression treatment therapy Market.
Insights about market determinants which are stimulating the Global depression treatment therapy Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.5.1. KEY FINDINGS
2.6.1. TAX LAWS
126.96.36.199. UNITED STATES
188.8.131.52. EUROPEAN UNION
184.108.40.206. REST OF THE WORLD
2.6.2. DRUG REGULATIONS
220.127.116.11. UNITED STATES
18.104.22.168. EUROPEAN UNION
22.214.171.124. REST OF THE WORLD
2.6.3. TYPE OF DEPRESSION DISORDERS
126.96.36.199. MAJOR DEPRESSION
188.8.131.52. BIPOLAR DEPRESSION
184.108.40.206. SEASONAL AFFECTIVE DISORDER
220.127.116.11. PSYCHOTIC DEPRESSION
18.104.22.168. POSTPARTUM DEPRESSION
22.214.171.124. ATYPICAL DEPRESSION
126.96.36.199. PERSISTENT DEPRESSIVE DISORDER
3. MARKET DETERMINANT
3.1.1. HIGH OCCURRENCE OF MENTAL HEALTH DISORDERS
3.1.2. INCREASING AWARENESS RELATED TO MENTAL HEALTH DISORDERS
3.1.3. UP SURGING MARKET FOR CHEAPER GENERIC DRUGS
3.1.4. UNHEALTHY LIFESTYLES RESULT IN THE INCREASED SALE OF ANTI-DEPRESSANTS
3.2.1. HIGH COST OF THERAPIES
3.2.2. SIDE EFFECTS OF DEPRESSION DRUGS
3.2.3. EXPIRING PATENTS AND DRYING PIPELINES
3.3.1. EMERGING MARKETS
3.3.2. INTRODUCTION OF NEW THERAPIES SUCH AS VIRTUAL REALITY
4. MARKET SEGMENTATION
4.1. DEPRESSION TREATMENT THERAPY MARKET BY DEPRESSION TYPE
4.1.1. SEASONAL AFFECTIVE DISORDER (SAD)
4.1.2. MAJOR DEPRESSION
4.1.3. DYSTHYMIA DISORDER
4.1.4. POSTPARTUM DEPRESSION
4.1.5. ATYPICAL DEPRESSION
4.1.6. PSYCHOTIC DEPRESSION
4.1.7. BIPOLAR DISORDER
4.2. DEPRESSION TREATMENT THERAPY MARKET BY DRUGS TYPE
4.2.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
188.8.131.52. FLUOXETINE (PROZAC)
184.108.40.206. SERTRALINE (ZOLOFT)
220.127.116.11. ESCITALOPRAM (LEXAPRO)
18.104.22.168. OTHERS SSRIS
4.2.2. ATYPICAL ANTIDEPRESSANTS
22.214.171.124. BUPROPION (WELLBUTRIN)
126.96.36.199. DULOXETINE (CYMBALTA)
188.8.131.52. VENLAFAXINE (EFFEXOR)
184.108.40.206. DESVENLAFEXINE (PRISTIQ)
220.127.116.11. OTHERS ATYPICAL ANTIDEPRESSANTS
4.2.3. TRICYCLIC ANTIDEPRESSANTS
4.3. DEPRESSION TREATMENT THERAPY MARKET BY DEPRESSION TREATMENT DEVICE
4.3.1. TRANSCRANIAL MAGNETIC
4.3.2. DEEP BRAIN STIMULATOR
4.3.3. VIRTUAL REALITY THERAPY
4.3.4. VAGUS NERVE SIMULATOR
4.3.5. SMART PHONE APPLICATIONS
4.3.6. OTHERS DEVICES
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.3. REST OF NORTH AMERICA
6.2.1. UNITED KINGDOM
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. ALLERGAN PLC
7.4. BRAIN RESOURCE COMPANY (BRC)
7.5. BRAINSWAY LTD.
7.6. BRISTOL MYERS SQUIBB
7.7. CYBERONICS, INC
7.8. ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC.
7.9. ELI LILLY AND COMPANY
7.10. JOHNSON & JOHNSON
7.11. LANNETT CO INC
7.12. LIFECARE NEURO PRODUCTS LIMITED
7.13. H. LUNDBECK A/S
7.15. MAYO CLINIC
7.16. MERCK & CO.
7.17. NEUROSIGMA, INC.
7.20. OTSUKA PHARMACEUTICALS
7.22. ROCHE HOLDING AG
7.24. SILVER OAK HEALTH
7.25. SUN PHARMACEUTICAL INDUSTRIES LTD.
7.26. TAKEDA PHARMACEUTICALS
7.27. TEVA PHARMACEUTICALS
7.28. THERAPY CHARLOTTE LLC
7.29. VALEANT PHARMACEUTICALS INTERNATIONAL
7.30. VISTAGEN THERAPEUTICS, INC.